Mayo Clinic researchers have developed fully humanized 3D bioprinted skin models to advance regenerative medicine and wound healing [1].
This development matters because it provides a viable non-animal alternative for pre-clinical testing. By using humanized models, researchers can more accurately predict how human skin will respond to personalized therapies and treatments before they reach clinical trials [1, 3].
The project was a collaboration between Mayo Clinic research facilities in Rochester, Minnesota, and the company CollPlant [1, 4]. The team, which includes Dr. Adam Feinberg of Carnegie Mellon University and Dr. Saranya Wyles of the Mayo Clinic, focused on creating tissue that mimics the complex structure of human skin [1].
A press release issued Oct. 16, 2025, said the model is designed to support a variety of medical applications [1]. These include the development of skin grafts for severe burns, and the creation of personalized therapy models tailored to a specific patient's genetic makeup [3, 4].
Beyond immediate wound care, the technology aims to reduce the reliance on animal testing in the pharmaceutical and cosmetic industries. Because the bioprinted skin is fully humanized, it offers a higher degree of biological relevance than traditional animal models [1, 3].
While skin is a more accessible tissue for bioprinting, the broader field of regenerative medicine continues to target more complex structures. Some industry estimates suggest a timeline of 10 to 15 years for the development of fully functional bioprinted organs [2].
“The new technology offers a non-animal alternative for pre-clinical testing.”
The shift toward fully humanized 3D bioprinting marks a transition from generic tissue engineering to precision medicine. By replacing animal models with human-derived bioprinted tissue, the medical community can potentially reduce the failure rate of new drugs in human trials and accelerate the delivery of personalized grafts for burn victims.
